Targeting MYC in combination with epigenetic regulators induces synergistic anti-leukemic effects in MLLr leukemia and simultaneously improves immunity.

"furthermore we analyzed publicly available patient data (gene expression omnibus (geo) series accession numbers gse42519 and gse13159) supporting the findings of high myc expression in leukemia and showing a downregulation in healthy cells upon myeloid differentiation ( fig 1 c bloodspot eu ).; rna-seq data have been analyzed as previously described and have been deposited in ncbi's gene expression omnibus with the accession number gse128342 ."

"Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."

"Funding CS was supported by the Wuerttembergischer Krebspreis, José Carreras Leukaemia Foundation (DJCLS 04R/2019), German Research Foundation (DFG, grant number 442788847) and the Clinician Scientist Program (390-0-0) of the Faculty of Medicine Tuebingen. JMSH was supported by a Margarete-von-Wrangell fellowship through the Ministry of Science, Research and the Arts Baden-Wuerttemberg, and together with TH, received funding from the decipherPD transnational consortium on Epigenomics of Complex Diseases (BMBF grant number 01KU1503)."